Targeting B7-H3 to treat advanced prostate cancer
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
This study is looking at how a protein called B7-H3 affects advanced prostate cancer that doesn't respond to regular hormone treatments, with the goal of finding better, more personalized therapies for patients with certain genetic changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11001836 on NIH RePORTER |
What this research studies
This research investigates the role of B7-H3 signaling in advanced prostate cancer, particularly in cases that are resistant to standard hormone therapies. By understanding how B7-H3 contributes to cancer progression and immune evasion, the researchers aim to develop targeted therapies that could improve treatment outcomes for patients with specific genetic mutations. The study utilizes advanced models to explore the effects of B7-H3 depletion on tumor growth and the immune environment, potentially leading to new biomarker-driven treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer, particularly those with PTEN and TP53 gene mutations.
Not a fit: Patients with early-stage prostate cancer or those without the specific genetic mutations being targeted may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with castration-resistant prostate cancer, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Zhao, Di — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhao, Di
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.